Acumen Pharmaceuticals Reports Q2 2026 Results, Updates Cash Position

What Happened

• On August 12, 2026, Acumen Pharmaceuticals, Inc. announced and furnished a press release reporting its results and business highlights for the quarter ended June 30, 2026 (filed on Form 8-K, Item 2.02).
• The company also posted an updated corporate presentation (Item 7.01) to its investor site reflecting its cash, cash equivalents and marketable securities balance as of June 30, 2026. The press release and presentation are attached to the 8-K as Exhibits 99.1 and 99.2.

Key Details

• Filing date: August 12, 2026; quarter covered: quarter ended June 30, 2026 (Q2 2026).
• Exhibit 99.1: Earnings press release dated August 12, 2026 (financial results and business highlights).
• Exhibit 99.2: Corporate presentation dated August 12, 2026, updated to show cash, cash equivalents and marketable securities as of June 30, 2026; available at https://investors.acumenpharm.com/news-events/presentations.
• Report signed on behalf of the company by Matthew Zuga, Chief Financial Officer and Chief Business Officer.

Why It Matters

• The 8-K provides the company’s latest quarterly results and updated liquidity information — key items investors monitor to assess financial health and near-term funding runway.
• The updated investor presentation and press release are the primary sources for the reported results and the company’s stated cash and marketable securities position; investors should review those exhibits for specifics on revenue, expenses, cash balances and business updates.